Physician profile
Ami Marie Caban
NPI 1619982295
$2,750.77
in general payments reported to CMS, 2019-2025
38 companies · $2,395 in 2025
The $2,395 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $20.57 · 2024: $220 · 2025: $2,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,334 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.50 |
| Education | $280.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $433.17 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $231.17 | 2025 | Imfinzi, Tagrisso, Calquence |
| Seagen INC. | $185.98 | 2025 | |
| Pharmaessentia USA Corporation | $139.20 | 2025 | Besremi |
| Pfizer INC. | $138.07 | 2025 | |
| Ethicon US, LLC | $136.30 | 2021-2022 | |
| Daiichi Sankyo INC. | $113.18 | 2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $109.67 | 2025 | Rybrevant, Erleada, Darzalex |
| Glaxosmithkline, LLC. | $91.79 | 2025 | Zejula, Jemperli, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $91.47 | 2025 | Fruzaqla, Iclusig |
| Novartis Pharmaceuticals Corporation | $86.83 | 2025 | |
| Merck Sharp & Dohme LLC | $83.79 | 2025 | Keytruda |
| Exelixis INC. | $66.13 | 2025 | Cabometyx |
| Fresenius Kabi USA, LLC | $59.76 | 2025 | Smoflipid |
| Lilly USA, LLC | $48.33 | 2025 | Jaypirca, Verzenio |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Caban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.